Replies to post #450 on The Moon Phase

[PoemStone]

RGEN. Regeneron Reports Third Quarter 2012 Financial and Operating Results
-- Third quarter EYLEA® (aflibercept) Injection sales increased 26% over second quarter to $244 million
-- Full year 2012 EYLEA U.S. sales forecast increased from $700 - $750 million to $790 - $815 million
-- Third quarter non-GAAP profit climbs to $217 million or $1.89 per diluted share
http://finance.yahoo.com/news/regeneron-reports-third-quarter-2012-103000608.html